

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 17, 2018

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for July 18, 2018 meeting
- IV. Secretary's report
- V. Old Business
 - A. Protocol for safe and efficient use of opioids (with the State's recommendations)
 - B. Protocol for safe and efficient use of Vivitrol® (naltrexone injection) [with the State's recommendation]
- VI. New Business
 - A. Proposed protocol for safe and efficient use of pancreatic enzymes
 - B. Medical Society of New Jersey Opioid Prescription Letter
- VII. Protocol review: Lyrica® (pregabalin)
- VIII. DURB Annual Report for SFY 2018 (July 1 thru June 30) – Board members packet
- IX. Informational Highlights/Reports
 1. Molina/NJ HMO 2nd Quarter 2018 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered/Antiviral drugs by amount paid
 4. Medication information:
 - (a) Study: CDC guidelines associated with declines in opioid prescribing
 - (b) Patients' Satisfaction Scores unaffected by Lowering of Opioid Dosages
 - (c) "Z" Drugs Significantly Boost Fracture Risk in Dementia Patients
 - (d) Tainted valsartan has been on the market for 4 years, FDA discovers
 - (e) Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries
 - (f) Anticonvulsant With Opioids Tied To Higher Mortality